Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Abstract

Antibody-mediated blockade of PD-L1 induced durable tumor regression (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks) in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00729664.).

Keywords

Affiliated Institutions

• Mayo Clinic US
• Bristol-Myers Squibb (United States) US
• Fred Hutch Cancer Center US
• Bristol-Myers Squibb (Germany) DE
• Angeles Clinic and Research Institute US
• Sidney Kimmel Comprehensive Cancer Center US
• Emory University US
• Cancer Institute (WIA) IN
• The University of Texas MD Anderson Cancer Center US
• Johns Hopkins University US
• St. Luke's Episcopal Hospital US
• Seattle Cancer Care Alliance US
• Cancer Research Center US
• Roswell Park Comprehensive Cancer Center US

Related Publications